Protease-Antiprotease Imbalance in Bronchiectasis

Area of Science:

• Pulmonary Medicine
• Biochemistry

Background:

• Airway inflammation is central to bronchiectasis.
• Protease-antiprotease imbalance contributes to bronchiectasis pathophysiology, onset, and progression.
• Overactive proteases and antiprotease deficiency exacerbate airway inflammation, leading to tissue damage.

Purpose of the Study:

• To explore the role of protease-antiprotease imbalance in bronchiectasis.
• To review current and developing therapeutic strategies targeting this imbalance.
• To highlight the potential for precision medicine in treating bronchiectasis.

Main Methods:

• Review of literature on protease-antiprotease balance in bronchiectasis.
• Analysis of associations between specific proteases (neutrophil elastase, MMPs) and disease severity.
• Examination of genetic factors (alpha1-antitrypsin deficiency) linked to bronchiectasis development.

Main Results:

• Imbalances in serine proteases and matrix metalloproteinases (MMPs) are associated with bronchiectasis.
• Active neutrophil elastase correlates with disease severity and poor outcomes.
• High MMP levels are linked to radiological and clinical severity.
• Severe alpha1-antitrypsin deficiency (PiSZ, PiZZ) is associated with bronchiectasis development.

Conclusions:

• Targeting protease activity offers potential therapeutic avenues for bronchiectasis.
• Developing inhibitors for neutrophil elastase and dipeptidyl-peptidase 1 are under investigation.
• Alpha1-antitrypsin supplementation is a viable treatment for severe deficiency.
• Precision medicine approaches targeting protease-antiprotease pathways can disrupt the disease cycle.